Remembering Leonard Nimoy

Last updated
Remembering Leonard Nimoy
Remembering Nimoy Poster.jpg
Theatrical release poster
Directed by Julie Nimoy, David Knight
Produced byJulie Nimoy
David Knight
David Zappone
CinematographyScott Yun
Edited byRon Frank
Production
company
Health Point Productions
Release date
Running time
1 hour
CountryUnited States
LanguageEnglish

Remembering Leonard Nimoy: His Life, Legacy and Battle with COPD is a 2017 American biographical documentary film about Leonard Nimoy and his battle with chronic obstructive pulmonary disease. It was produced and directed by his daughter and son-in-law, Julie Nimoy and David Knight.

Contents

Synopsis

The film focuses on the life and career of actor Leonard Nimoy and his battle with chronic obstructive pulmonary disease (COPD), along with his wishes of increasing awareness and prevention of the illness. Narrated by his daughter Julie with a voiceover appearance by Star Trek actor John de Lancie, the film features interviews with Nimoy's immediate family, his personal physician and private nurse, and lung disease experts. [1]

Production

Nimoy revealed during a January 2014 appearance on Piers Morgan Live that he was suffering from chronic obstructive pulmonary disease. He became an advocate and activist for COPD awareness thereafter, and posted on social media about the dangers of smoking. His daughter Julie Nimoy collaborated with his son-in-law, filmmaker David Knight, in producing a documentary that would chronicle Nimoy's battle with the disease.

After Nimoy's death in 2015, the focus of the film was changed to serve as a remembrance of his life. [2] With funding from commercial and private contributors, Knight and Julie Nimoy began production in January 2016. [3] [4] Working titles included COPD: "Highly Illogical"— A Special Tribute to Leonard Nimoy. [3] [4] The documentary’s first trailer and poster were released in February 2017.

Release

A preliminary version of the film was screened on April 23, 2017 at the Newport Beach Film Festival, and was followed by a Q & A with Nimoy's family. [5] In June 2017, American Public Television acquired the distribution rights to broadcast the film on its PBS affiliates nationwide. [6] [7] [8] [9]

Related Research Articles

<span class="mw-page-title-main">Leonard Nimoy</span> American actor (1931–2015)

Leonard Simon Nimoy was an American actor, famed for playing Spock in the Star Trek franchise for almost 50 years. This includes originating Spock in the original Star Trek series in 1966, then Star Trek: The Animated Series, the first six Star Trek films, and Star Trek: The Next Generation. Nimoy also directed films, including Star Trek III: The Search for Spock (1984) and Star Trek IV: The Voyage Home (1986), and appeared in several films, television shows, and voice acted in several video games. Outside of acting, Nimoy was a film director, photographer, author, singer, and songwriter.

<span class="mw-page-title-main">Alpha-1 antitrypsin deficiency</span> Medical condition

Alpha-1 antitrypsin deficiency is a genetic disorder that may result in lung disease or liver disease. Onset of lung problems is typically between 20 and 50 years of age. This may result in shortness of breath, wheezing, or an increased risk of lung infections. Complications may include chronic obstructive pulmonary disease (COPD), cirrhosis, neonatal jaundice, or panniculitis.

<i>I Am Spock</i> Leonard Nimoys second autobiography

I Am Spock is the second volume of actor and director Leonard Nimoy's autobiography. The book was published in 1995, four years after the release of the last Star Trek motion picture starring the entire original cast, and covers the majority of Nimoy's time with Star Trek in general and Mr. Spock in particular. The book's title was a reference to the first volume of his autobiography, I Am Not Spock, which had been published in 1975. At that time, Nimoy had sought to distance his own personality from that of the character of Spock, although he nonetheless remained proud of his time on the show. Negative fan reaction to the title gave Nimoy the idea for the title of the second volume.

<span class="mw-page-title-main">Long-acting beta-adrenoceptor agonist</span> Drug prescribed for asthma patients

Long-acting β adrenoceptor agonists are usually prescribed for moderate-to-severe persistent asthma patients or patients with chronic obstructive pulmonary disease (COPD). They are designed to reduce the need for shorter-acting β2 agonists such as salbutamol (albuterol), as they have a duration of action of approximately 12 hours in comparison with the 4-to-6-hour duration of salbutamol, making them candidates for sparing high doses of corticosteroids or treating nocturnal asthma and providing symptomatic improvement in patients with COPD. With the exception of formoterol, long-acting β2 agonists are not recommended for the treatment of acute asthma exacerbations because of their slower onset of action compared to salbutamol. Their long duration of action is due to the addition of a long, lipophilic side-chain that binds to an exosite on adrenergic receptors. This allows the active portion of the molecule to continuously bind and unbind at β2 receptors in the smooth muscle in the lungs.

<span class="mw-page-title-main">Erdosteine</span> Chemical to treat chronic bronchitis

Erdosteine is a molecule with mucolytic activity. Structurally it is a thiol derivative characterized by the presence of two thiol groups. These two functional sulfhydryl groups contained in the molecule are released following first-pass metabolism with the conversion of erdosteine into its pharmacologically active metabolite Met-I.

<span class="mw-page-title-main">Bronchitis</span> Inflammation of the large airways in the lungs

Bronchitis is inflammation of the bronchi in the lungs that causes coughing. Bronchitis usually begins as an infection in the nose, ears, throat, or sinuses. The infection then makes its way down to the bronchi. Symptoms include coughing up sputum, wheezing, shortness of breath, and chest pain. Bronchitis can be acute or chronic.

<span class="mw-page-title-main">Obstructive lung disease</span> Category of respiratory disease characterized by airway obstruction

Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung result from narrowing (obstruction) of the smaller bronchi and larger bronchioles, often because of excessive contraction of the smooth muscle itself. It is generally characterized by inflamed and easily collapsible airways, obstruction to airflow, problems exhaling, and frequent medical clinic visits and hospitalizations. Types of obstructive lung disease include; asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Although COPD shares similar characteristics with all other obstructive lung diseases, such as the signs of coughing and wheezing, they are distinct conditions in terms of disease onset, frequency of symptoms, and reversibility of airway obstruction. Cystic fibrosis is also sometimes included in obstructive pulmonary disease.

<span class="mw-page-title-main">Indacaterol</span> Chemical compound

Indacaterol is an ultra-long-acting beta-adrenoceptor agonist developed by Novartis. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic obstructive pulmonary disease (COPD). It is delivered as an aerosol formulation through a dry powder inhaler.

<span class="mw-page-title-main">FEV1/FVC ratio</span> Ratio used in the diagnosis of lung disease

The FEV1/FVC ratio, also called Tiffeneau-Pinelli index, is a calculated ratio used in the diagnosis of obstructive and restrictive lung disease. It represents the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration (FEV1) to the full, forced vital capacity (FVC). The result of this ratio is expressed as FEV1%.

Pulmonary rehabilitation, also known as respiratory rehabilitation, is an important part of the management and health maintenance of people with chronic respiratory disease who remain symptomatic or continue to have decreased function despite standard medical treatment. It is a broad therapeutic concept. It is defined by the American Thoracic Society and the European Respiratory Society as an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities. In general, pulmonary rehabilitation refers to a series of services that are administered to patients of respiratory disease and their families, typically to attempt to improve the quality of life for the patient. Pulmonary rehabilitation may be carried out in a variety of settings, depending on the patient's needs, and may or may not include pharmacologic intervention.

<span class="mw-page-title-main">Acute exacerbation of chronic obstructive pulmonary disease</span> Medical condition

An acute exacerbation of chronic obstructive pulmonary disease, or acute exacerbations of chronic bronchitis (AECB), is a sudden worsening of chronic obstructive pulmonary disease (COPD) symptoms including shortness of breath, quantity and color of phlegm that typically lasts for several days.

<span class="mw-page-title-main">Tiotropium bromide</span> Long-acting bronchodilator in the maintenance of COPD and asthma

Tiotropium bromide, sold under the brand name Spiriva among others, is a long-acting bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Specifically it is used during periods of breathing difficulty to prevent them from getting worse, rather than to prevent them from happening. It is used by inhalation through the mouth. Onset typically begins within half an hour and lasts for 24 hours.

<span class="mw-page-title-main">Chronic obstructive pulmonary disease</span> Lung disease involving long-term poor airflow

Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation. The main symptoms include shortness of breath and a cough, which may or may not produce mucus. COPD progressively worsens, with everyday activities such as walking or dressing becoming difficult. While COPD is incurable, it is preventable and treatable.

<span class="mw-page-title-main">Olodaterol</span>

Olodaterol is an ultra-long-acting β adrenoreceptor agonist (ultra-LABA) used as an inhalation for treating people with chronic obstructive pulmonary disease (COPD). It is manufactured by Boehringer Ingelheim.

The Dutch hypothesis provides one of several biologically plausible explanations for the pathogenesis of chronic obstructive pulmonary disease (COPD), a progressive disease known to be aetiologically linked to environmental insults such as tobacco smoke.

<span class="mw-page-title-main">Umeclidinium bromide</span> Chemical compound

Umeclidinium bromide is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also approved for this indication in combination with vilanterol and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.

<span class="mw-page-title-main">Emphysema</span> Medical condition

Emphysema, or pulmonary emphysema, is a lower respiratory tract disease, characterised by air-filled spaces (pneumatoses) in the lungs, that can vary in size and may be very large. The spaces are caused by the breakdown of the walls of the alveoli and they replace the spongy lung parenchyma. This reduces the total alveolar surface available for gas exchange leading to a reduction in oxygen supply for the blood. Emphysema usually affects the middle aged or older population because it takes time to develop with the effects of tobacco smoking, and other risk factors. Alpha-1 antitrypsin deficiency is a genetic risk factor that may lead to the condition presenting earlier.

<span class="mw-page-title-main">Revefenacin</span> Chemical compound

Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.

Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a fixed-dose combination inhaled medication that is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The medications work in different ways: fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta-agonist (LABA).

<span class="mw-page-title-main">Julie Nimoy</span> Daughter of Sandra Zober and Leonard Nimoy

Julie Nimoy is an American film producer and director. Nimoy is the daughter of actors Leonard Nimoy and actress and costume designer Sandra Zober.

References

  1. "WATCH: New 'Remembering Leonard Nimoy' Trailer | TREKNEWS.NET". TREKNEWS.NET. 2017-02-05. Retrieved 2018-02-07.
  2. Ulanoff, Lance. "Remembering Leonard Nimoy looks at the full life and private struggle of a beloved actor". Mashable. Retrieved 2018-02-07.
  3. 1 2 "COPD: Highly Illogical - A Special Tribute to Leonard Nimoy". FirstGiving. Retrieved 2018-02-07.
  4. 1 2 "COPD: Highly Illogical-A Tribute to Leonard Nimoy". Indiegogo. Retrieved 2018-02-07.
  5. "Remembering Leonard Nimoy - The Newport Beach Film Festival". The Newport Beach Film Festival. Retrieved 2018-02-07.
  6. "Remembering Leonard Nimoy Doc To Start Airing Sunday". StarTrek.com. Retrieved 2018-02-07.
  7. "Leonard Nimoy Documentary To Air Nationally On PBS". ComicBook. Retrieved 2018-02-07.
  8. "REMEMBERING LEONARD NIMOY". American Public Television. Retrieved 2018-02-07.
  9. "| Remembering Leonard Nimoy". WGBH-TV . Retrieved 2018-02-07.